FRANCE – ABL Biotechnologies, a South Korean biotechnology firm, has signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new Parkinson’s disease therapy candidate.…
Read MoreTag: alpha-synuclein
Novartis pays US$150 million to gain rights to UCB’s Parkinson’s drug
BELGIUM – Novartis is putting US$150 million into a Parkinson’s disease drug candidate that is competing with drugs in development at companies such as Roche and AstraZeneca. Novartis will pay…
Read More